Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic/Pharmacodynamic Model

Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic/Pharmacodynamic Model

Therapeutic drug monitoring is considered to be an effective tool for the individualized use of voriconazole. However, drug concentration measurement alone doesn’t take into account the susceptibility of the infecting microorganisms to the drug. Linking pharmacodynamic data with the pharmacokinetic...

Full description

Bibliographic Details
Main Authors:	Ping Yang, Wei Liu, Jiajia Zheng, Yuanyuan Zhang, Li Yang, Na He, Suodi Zhai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Series:	Frontiers in Pharmacology
Subjects:	voriconazole individual pharmacokinetic parameters population pharmacokinetic Monte Carlo simulation minimal inhibitory concentration (MIC)
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.711187/full

Similar Items

Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
by: Zhiwen Jiang, et al.
Published: (2022-09-01)

Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases
by: Buddharat Khan-asa, et al.
Published: (2020-09-01)

Population Pharmacokinetics of Orally Administered Clindamycin to Treat Prosthetic Joint Infections: A Prospective Study
by: Léo Mimram, et al.
Published: (2022-10-01)

Pharmacokinetics and safety of two Voriconazole formulations after intravenous infusion in two doses in healthy Chinese subjects
by: Xin Li, et al.
Published: (2023-03-01)

Pharmacokinetics, safety of a single dose and multiple doses of voriconazole injection of two formulations, in Chinese healthy volunteers
by: Chunqi Huang, et al.
Published: (2022-12-01)

Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy
by: Zhiling Li, et al.
Published: (2021-05-01)

Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation
by: Saeed Alqahtani, et al.
Published: (2021-11-01)

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
by: Jae Ha Lee, et al.
Published: (2021-11-01)

Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations
by: Zhi-ling Li, et al.
Published: (2018-06-01)

Pharmacokinetic/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation
by: Pan Ma, et al.
Published: (2023-06-01)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
by: Yutao Lou, et al.
Published: (2023-08-01)

Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: A comparison of Michaelis-Menten and theory-based pharmacokinetic models
by: Xiao-Jun Cai, et al.
Published: (2022-11-01)

Pharmacokinetics and Pharmacodynamics of Tildipirosin Against Pasteurella multocida in a Murine Lung Infection Model
by: Dongping Zeng, et al.
Published: (2018-05-01)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
by: Wang H, et al.
Published: (2021-11-01)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique [Corrigendum]
by: Wang H, et al.
Published: (2023-11-01)

Interaction and potential mechanisms between atorvastatin and voriconazole, agents used to treat dyslipidemia and fungal infections
by: Tianrong Xun, et al.
Published: (2023-05-01)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
by: Ji-Sang Lee, et al.
Published: (2021-05-01)

Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation
by: Yu W, et al.
Published: (2017-06-01)

A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model
by: Taotao Wang, et al.
Published: (2018-06-01)

Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation
by: Jiaojiao Zhong, et al.
Published: (2024-01-01)

Concept and utility of population pharmacokinetic and pharmacokinetic/pharmacodynamic models in drug development and clinical practice
by: Roganović Maša, et al.
Published: (2021-01-01)

Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant <i>Escherichia coli</i>
by: Johanna Seeger, et al.
Published: (2021-05-01)

Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
by: Jörn Grensemann, et al.
Published: (2021-10-01)

Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling
by: Yong Kyun Kim, et al.
Published: (2022-05-01)

Impact of extracorporeal membrane oxygenation on voriconazole plasma concentrations: A retrospective study
by: Qinghua Ye, et al.
Published: (2022-08-01)

Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation
by: O. Asuphon, et al.
Published: (2016-09-01)

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
by: Josefine Schulz, et al.
Published: (2022-02-01)

Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis
by: Chao‐Yang Chen, et al.
Published: (2023-04-01)

Pharmacokinetic–pharmacodynamic cutoff values for benzylpenicillin in horses to support the establishment of clinical breakpoints for benzylpenicillin antimicrobial susceptibility testing in horses
by: Elodie A. Lallemand, et al.
Published: (2023-10-01)

Association between Augmented Renal Clearance and Inadequate Vancomycin Pharmacokinetic/Pharmacodynamic Targets in Chinese Adult Patients: A Prospective Observational Study
by: Jinjin Zhao, et al.
Published: (2022-06-01)

Optimizing gentamicin dosing in different pediatric age groups using population pharmacokinetics and Monte Carlo simulation
by: Ragia H. Ghoneim, et al.
Published: (2021-08-01)

Systematic Evaluation of Voriconazole Pharmacokinetic Models without Pharmacogenetic Information for Bayesian Forecasting in Critically Ill Patients
by: Simon Kallee, et al.
Published: (2022-09-01)

Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach
by: Qingxia Liu, et al.
Published: (2022-05-01)

Population pharmacokinetics of tigecycline in critically ill patients
by: Xiangru Luo, et al.
Published: (2023-03-01)

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies
by: Zhao Y, et al.
Published: (2022-03-01)

Basic pharmacokinetics and pharmacodynamics : an integrated textbook and computer simulations /
by: Rosenbaum, Sara (Sara E.)
Published: (c201)

Population Pharmacokinetics and Dosing Regimen of Lithium in Chinese Patients With Bipolar Disorder
by: Zi-bin Jin, et al.
Published: (2022-07-01)

Pharmacokinetic-pharmacodynamic modeling and simulation /
by: 192959 Bonate, Peter L.
Published: (2005)

Prediction of marbofloxacin dosage for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida by pharmacokinetic/pharmacodynamic modelling
by: Lucy Dorey, et al.
Published: (2017-07-01)

Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
by: Peile Wang, et al.
Published: (2021-11-01)